Zobrazeno 1 - 10
of 50
pro vyhledávání: '"M V Kozhevnikova"'
Autor:
S. S. Markin, E. A. Ponomarenko, Yu. A. Romashova, T. O. Pleshakova, S. V. Ivanov, F. N. Bedretdinov, S. L. Konstantinov, A. A. Nizov, A. G. Koledinskii, A. I. Girivenko, K. M. Shestakova, P. A. Markin, N. E. Moskaleva, M. V. Kozhevnikova, Zh. Yu. Chefranova, S. A. Appolonova
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Cardiovascular disease (CVD) represents one of the main causes of mortality worldwide and nearly a half of it is related to ischemic heart disease (IHD). The article represents a comprehensive study on the diagnostics of IHD through the targ
Externí odkaz:
https://doaj.org/article/87f6a3e5d3ef44cea37af3a5a07f2718
Autor:
M. V. Kozhevnikova, E. O. Korobkova, A. V. Krivova, A. V. Kukharenko, N. E. Moskaleva, K. M. Shestakova, N. V. Mesonzhnik, A. A. Ageev, A. A. Boldin, A. Brito, S. А. Appolonova, E. V. Privalova, Y. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 3, Pp 230-239 (2023)
Aim. Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders.Material an
Externí odkaz:
https://doaj.org/article/61c3c7ab4d554143906bdba8748d9c90
Autor:
A. V. Krivova, M. V. Kozhevnikova, E. O. Korobkova, V. Yu. Zektser, E. A. Zheleznykh, А. A. Ageev, N. E. Moskaleva, A. V. Kukharenko, S. A. Appolonova, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 3, Pp 297-305 (2022)
Aim. To evaluate changes in the profile of aromatic amino acids (AAA) in patients with cardiovascular diseases (CVD): hypertension and coronary artery disease (CАD) in comparison with healthy study participants.Material and methods. One hundred and
Externí odkaz:
https://doaj.org/article/635f8136ef1b4717b3c5152341bfb1f8
Autor:
F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, D. A. Yatsenko, А. V. Emelianov, A. S. Lishuta, N. V. Khabarova, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 3, Pp 408-413 (2021)
Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women)
Externí odkaz:
https://doaj.org/article/ba9f82e067fd4a27bdea76adb8b2bd79
Autor:
F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 3 (2022)
Aim. To assess the relationship between fibrosis markers and structural and functional parameters in patients with various types of hypertrophic cardiomyopathy (HCM).Material and methods. This prospective comparative non-randomized study included 49
Externí odkaz:
https://doaj.org/article/88221651038545c98eec9fc4c8b2acc1
Autor:
O. O. Voronkova, A. A. Starzhevskaia, V. G. Skachek, E. F. Rogova, G. B. Abdullaeva, O. E. Buyanova, M. V. Kozhevnikova, Yu. N. Belenkov
Publikováno v:
Meditsinskiy sovet = Medical Council. :50-56
The subacute period of coronavirus infection is a 4- to-12-week period after acute illness associated with the SARS-CoV-2 infection. A range of bronchopulmonary symptoms in the subacute period of COVID-19 includes cough, shortness of breath, reduced
Autor:
Yu. A. Danilogorskaya, E. A. Zheleznykh, E. A. Privalova, Yu. N. Belenkov, A. A. Shchendrigina, M. V. Kozhevnikova, G. A. Shakaryants, V. Y. Zektser, A. S. Lishuta, I. S. Ilgisonis
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 15, Iss 3, Pp 328-334 (2019)
Aim. To study some vascular remodeling markers in hypertensive patients depending on the presence of type 2 diabetes mellitus.Material and methods. The study included patients with essential hypertension 1-2 degrees of increase in blood pressure with
Externí odkaz:
https://doaj.org/article/8599c7d6eda940c19466709b6e680653
Autor:
Yu. N. Belenkov, E. V. Privalova, V. Y. Kaplunova, V. Y. Zektser, N. N. Vinogradova, I. S. Ilgisonis, G. A. Shakaryants, M. V. Kozhevnikova, A. S. Lishuta
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 5, Pp 757-764 (2018)
Obesity is one of the leading and the most serious risk factors of cardiovascular diseases. Overweight provokes many metabolic and hemodynamic disorders. About 30% of inhabitants of the planet have overweight and prevalence of obesity increases by 10
Externí odkaz:
https://doaj.org/article/a2678771da9b4894a1eb1dc5551db2f1
Autor:
A. A. Ageev, M. V. Kozhevnikova, A. V. Emelyanov, A. V. Krivova, Yu. F. Shumskaya, L. M. Musaeva, L. V. Popova, Yu. I. Naymann, G. B. Abdullaeva, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 62:23-29
Aim To evaluate functional changes in the heart in the long-term following COVID-19 in patients with chronic heart failure (CHF).Material and methods Case reports of 54 patients aged 69.1±9.7 years who had COVID-19 from January 2021 through January
Autor:
M. V. Kozhevnikova, A. V. Krivova, E. O. Korobkova, A. A. Ageev, K. M. Shestakova, N. E. Moskaleva, S. A. Appolonova, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 62:40-48
Aim To compare serum concentrations of tryptophane (Trp) and its metabolites in subjects with no cardiovascular disease (CVD) and patients with СVD, including arterial hypertension (AH) and ischemic heart disease (IHD).Material and methods This stud